Susan O'Brien, Maher Albitar and Francis J. Giles Pages 663 - 675 ( 13 )
MoAb-based therapies are evolving into the first broad-spectrum class of targeted antileukemic therapy. Developments in many areas, including computer modeling of receptors and ligands, and increasing sophistication in recombinant technologies may result in a rapid increase in the number and complexity of MoAbs available. We can anticipate an increase in the number of safer conjugates being delivered to leukemia cells. Further understanding of the in vitro mechanisms involved in tumor cell killing by MoAb will be important in maximizing the efficacy of this approach.
Rituximab, cytotoxicity, hypertension, cyclophosphamide, Alemtuzumab
Department of Leukemia,University of Texas, M.D. Anderson Cancer Center, 1515 HolcombeBoulevard, Box 428, Houston, Texas, 77030, USA.